• Bostwick D, Neumann R, Qian J, Cheng L. Reversibility of Prostatic Intraepithelial Neoplasía: Implications for Chemoprevention
• European Urology 35(5-6):492-495, 1999
• Bowling A. Measuring Health. A review of quality of life measurement scales. Buckingham University Press 1997
• Boyle P, Robertson C, Lowe F. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic
• benign prostatic hyperplasía. BJU Int April 93(6):751-756, 2004
• Braeckman J, Denis L, de Leval J. A double blind placebo controlled study of the plant extract serenoa repens in the treatment of
• benign hyperplasía of the prostate. European Journal of Clinical Research 1997;9:247-59
• Bravi F, Bosetti C, Dal Máso et al. Food Groups and risk of benign prostatic hyperplasía. Urology 67(1): 73-79,Jan 2006
• Bravi F et al. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasía. Urol 67(6):1205-1211, Jun 2006
• Brawer M et al.Effect of finasteride and/or terazosin on serum PSA:results of VA Cooperative Study #359.Prost 39:234-239, 1999
• Brawer M. Prostatic intraepithelial neoplasía: a premalignant lesion. Hum Pathol 23(3): 242 Mar 1992
• Brawley O, Barnes S, Parnes H. The future of prostate cáncer prevent. Ann NY Acad Sci 2001 Dec 952:145-52
• Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign
• prostatic hyperplasía: A multicentre trial in central Europe. Curr Med Res Opin 14 (3): 127-139, 1998
• Broghamer W et al. Relationship between serum selenium levels and patients with carcinoma. Cáncer 37(3): 1384-1388, 1976. Brooks J, et al. Plasma selenium level before diagnosis and the risk of prostate cáncer development. J Urol 168(2), 2002 Brossner C, Petritsch K, Fink K. Phytoestrogen tissue levels in benign prostatic hyperplasía and prostate cáncer and their
• association with prostatic diseases. Urology. 64(4):707-711, Oct 2004
• Brown M, Hart C, Gazi E et al. Omega-3 poly-unsatured fatty acids inhibit omega-6 poly-unsatured fatty acid directed metastasís
• towards human bone marrow stroma. Abstract # 577, Eur Urol suppl 5(2):166, 2006
• Buck A, Cox R, Rees R, et al Treatment of outflow tract obstruction due to benign prostatic hyperplasía with the pollen extract,
• cernilton. A double-blind, placebo-controlled study. Br J Urol 1990 Oct;66(4):398-404.
• Buck A, Mahendra V, Bayne C, et al. An investigation into the “in vivo” effect of Permixon an extract of the american dwarf palm,
• Serenoa repens on human benign prostatic hyperplasía. Program Abstracts AUA Annual Meeting J Urol 167(4) April 2002 Abstracts # 1488
• Bullock T et al. Emerging drug therapies for benign prostatic hyperplasía. Exp Opin on Emerg Drugs, March 11(1): 111-123, 2006 Byers T, Nestle M, McTiernan A et al. American Cáncer Society 2001 Nutrition and Physical Activity Guidelines Advisory
• Committee. American Cáncer Society guidelines on nutrition and physical activity for cáncer prevention: Reducing the risk of cáncer with
• healthy food choices and physical activity. CA Cáncer Journal for Clinicians, 52(2), 92-119, Mar-Apr 2002
• Bylund A, Zhang J, Bergh A. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate
• adenocarcinoma in nude mice. Prostate 2000;42(4):304-314
• Cal C, Uslu R, Gunaydin G et al. Doxazosin: a new cytotoxic agent for prostate cáncer? BJU Int. 85(6):672-675, April 2000 Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cáncer: Prolongation of survival times in terminal
• human cáncer. Proc Natl Acad Sci USA 73:3685-3689,1976
• Campbell S, Bouck N. Harnessing the tumor-fighting power of angiogenesis. Cont Urol 8(6) 27-40, Junio 1996
• Canene-Adams K, Lindshield B, Wang S, et al. Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning
• R3327-H Prostate Adenocarcinomás. Cáncer Res 67(2): 836 – 843, Jan 2007
• Capodice J, Bemis D, Buttyan R, et al. Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain
• syndrome. Evid Based Complement Alternat Med. 2005 Dec; 2(4):495-501.
• Carbin B, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasía with phytosterols. Br J Urol. 1990 Dec;66(6):639-41.
• Carter B, Steinberg G, Beaty T. Familial risk factors for prostate cáncer. Cáncer Surveys 11: 5-13, 1991.
• Carraro J, Raynaud J et al. Comparison of phytotherapy (Permixon®) with Finasteride in the treatment of benign prostate
• hyperplasía: a randomized international study of 1.098 patients. Prostate 29:231-240,1996
• Cassileth B, Vickers A. Complementary and Alternative Medicine. Ch 55: 721-735 in Prostate Cáncer. Principles & Practice. Kantoff- Carroll, D Amico. Lippincott Williams & Wilkins, 2002.
• Cassileth B, Lusk E, Strouse T. Contemporary unorthodox treatments in cáncer Medicine: a study of patients, treatments and practitioners. Ann Intern Med 101:105-112, 1984
• Caygill C, Charlett A, Hill M.Fat, fish, fish oil and cáncer. Br J Cáncer 74(1):159-164, Jul 1996
• Cerhan J, Torner J, Lynch C. Association of smoking, body máss and physical activity with risk of prostate cáncer in the Iowa 65 Rural Health Study (United States) Cáncer Causes Control 8:229-238,1997
• Cerutti P, Trump B. Inflammation and oxidative stress in carcinogenesis. Cáncer Cells 3:1-7,1991
• Cerutti P, Shah G, et al. Oxidant carcinogenesis and antioxidant defense. Ann NY Acad Sci 663:158-166,1992.
• Chang J, Stampfer M, et al. Supplemental vitamin E intake and prostate cáncer risk in a large cohort of men in the United States. Cáncer Epidemiol Biomarkers Prev 8:893-899,1999
• Chan J, Elkin E, Silva S et al. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cáncer. Urology 66: 1223-1228, 2005
• Chan J, Giovannucci E, Andersson S, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cáncer. Cáncer Causes Control. 9(6):559-566, Dec 1998
• Chan J, Willett W, Giovannucci E, et al. Diet after diagnosis and the risk of prostate cáncer progression, recurrence, and death (United States). Cáncer Causes Control. 17(2):199-208, March 2006
• Chatelain C, Denis L, Foo J et al. 5th International Consultation on BPH. Recommendations of the International Scientific Committee: Evaluation and Treatment of Lower Urinary Tract Symptoms (LUTS) in Older Men. In: Chatelain C, Denis L, Foo K et al (eds). Benign prostatic hyperplasía; 5th International Consultation on Benign Prostatic Hyperplasía (BPH)-June 25-28, 2000, Paris. Plymouth, Plymbridge Distributors Ltd. 519-534, 2001
• Chavez M, Chavez P. Herbal Medicine:545-563 in Nutritional Oncology and Integrative Cáncer Care, Complementary & Alternative Medicine. Novey DW. Mosby 2000
• Chaudhary A, Pechan T, Willett K et al. Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines. Toxicol Appl Pharmacol. 220(2):197-210, April 2007
• Cheah P, Liong M et al. Terazosin Therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 169(2) 592-596, Feb 2003
• Cherniak. Alternative Medicine for the Elderly. 473 pg, 2003 Springer
• Chiappelli F. Differential effect of beta-endorphin on three human cytotoxic cell populations. Int J Inmunophar 13:291-297,1991
• Chon J, Borkowski A, Partin A, et al. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasía. J Urol. 161(6):2002-2008, Jun 1999
• Chung L et al. Stromal-Epithelial Interaction. Implications for prostate tumorigenesis.The Cáncer Bulletin 45 (5);430-435 ,1993
• Chung L, Zhau H, Wu T. Development of human prostate cáncer models for chemoprevention and experimental therapeutics studies. J Cell Biochem Suppl 28-29:174-181, 1997
• Clark L et al., Effects of selenium supplementation for cáncer prevention in patients with carcinoma of the skin. A randomized controlled trial, Nutritional Prevention of Cáncer Study Group. Journal of the American Medical Association, 276: 1957-1963, 1996
• Clark L, Marshall J. Randomized, controlled Chemoprevention trials in populations at very high risk for prostate cáncer: elevated prostate especific antigen and high-grade prostatic intraepithelial neoplasía. Urol 57(suppl 4A):185-187,2001
• Clark P, Craig H, Borden L, et al. Phase I-II Prospective dose-escalating trial of Lycopene in patients with biochemical relapse of prostate cáncer after definitive local therapy. Urology 67(6): 1257-1261, Jun 2006
• Clark L, Dalkin B, Krongrad A et al. Decreased incidence of prostate cáncer with selenium supplementation: results of a double-blind cáncer prevention trial. BJU 81:730-734, 1998
• Clark L, Alberts D. Selenium and Cáncer: Risk or Protection? J Nat Cáncer Instit 87(7):437-475, April 5, 1995.
• Clark P, Craig H, Borden L, et al. Phase I-II Prospective dose-escalating trial of Lycopene in patients with biochemical relapse of prostate cáncer after definitive local therapy. Urology 67(6): 1257-1261, Jun 2006
• Clement P. Lessons from basíc research in selenium and cáncer prevention. j Nutrition 128:1845-1854 1998
• Clinton S, Emenhiser C et al. Cis-trans lycopene isomers, carotenoids and retinol in the human prostate. Cáncer Epidemiol Biomarkers Prev 1996 Oct 5(10):823-33
• Clinton S. Lycopene: Chemistry, biology and implications for human health and disease. Nutrition Reviews 56:35-51, 1998
• Coffey D. Similarities of prostate and breast cáncer: Evolution, diet and estrogens. Urology 57(Suppl 4A): 31-38, 2001
• Cohen R et al. Neuro-Endrocrine Cells: A new prognostic parameter in Prostate Cáncer. Br J Urol 68:258-262, 1991
• Colditz G. Selenium and cáncer prevention. JAMA 276:1984-1985, 1996
• Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL.Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cáncer evolution? J Urol 173(6):1969,1974, Jun 2005
• Colli J et al. Comparison of prostate cáncer mortality rates with changes in dietery practices in the United States from 1930 to 2000. Abstracts # 133 J Urol 175(4):42 Suppl May 2006
• Cook N, Stampfer M, Ma J. Beta carotene supplementation and total and prostate cáncer incidence among randomized participants with low baseline plasma levels in the Physicians´Health Study Cáncer 86:1783-1792,1999
• Cook N, Le I, Manson J, et al. Effects of beta-carotene supplementation on cáncer incidence by baseline characteristics in the Physicians' Health Study (United States). Cáncer Causes Control 11:617-626, 2000
• Connolly J, Coleman M, Rose D. Effects of dietary fatty acids on DU145 human prostate cáncer cell growth in athymic nude mice. Nutrition and Cáncer 29(2): 114-119, 1997.
• Costello L et al. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cáncer. The Prostate 35:285-296,1998.